pharma · Interstitial Lung Disease (ILD) · Gastrointestinal Disease
ZhongShan Hospital, Fudan
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Interstitial Lung Disease (ILD), Gastrointestinal Disease, Takayasu Arteritis. NovaPharmaNews links 3 clin
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1936
- Employees
- 624
- Programs
- 3
- Drugs
- 8
- Patents
- 0
ACE001-RI001
Phase 1 · mab · Interstitial Lung Disease (ILD)
ACE001-RI001 for Interstitial Lung Disease (ILD) is a Phase 1 program (mab) at Shanghai Zhongshan Hospital with 1 ClinicalTrials.gov record(s).
Internal code ACE001-RI001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Zhongshan Hospital
- Phase
- Phase 1
- Modality
- mab
- Indication
- Interstitial Lung Disease (ILD)
- Status
- active
- Trials
- 1